Abstract Body

Background:

HIV-1 remains significant global health challenge, requiring continuous efforts to develop innovative therapeutic approaches. Clinical use of mAb needs multiple infusions and for BiTEs is limited by short half-life in blood, demanding continuous infusion resulting in high costs inconvenience and time-consumption. We describe the development of DNA-launched, bispecific T cell engagers that redirect T cells towards killing target HIV infected cells. These are highly specific Broadly neutralizing Killers (BnKs) that demonstrate long half-lives (LHL) in-vivo.

Methods:

We designed DNA-launched LHL- BnKs with bispecific scFvs and a Fc fragment having Fc effector-null mutations to abrogate Fcγ receptor binding. We evaluated in-vitro and in-vivo expression of DNA launched LHL-BnKs and characterized functionality. ELISA and flow cytometry were used to demonstrate binding studies, pseudo-neutralization assays to test neutralizing potential against a global virus panel. A novel cell based Xcelligence assay was designed which uses impedance as a readout for killing activity. In-vivo pharmacokinetics were evaluated by inoculating the DNA launched LHL-BnKs in BALB/c mice.

Results:

DNA launched PGDM1400, 3BNC117 and PGT121 LHL-BnKs respectively were designed and optimized for expression both in-vitro and in-vivo. Binding studies demonstrate that these molecules bind to CD3 in a concentration dependent manner. They also demonstrated binding to CD3+T cells and neutralized a global panel of HIV-1 Tier 2/3 viruses with high potency and specificity. The LHL-BnKs displayed potent killing of HIV-1 infected target cells with nanogram/ml IC50 for killing. Combination therapy of 10-1074 and 3BNC117 did significantly reduce viral rebound in clinical trials where the groups received up to 8 infusions of 3BNC117 during the 24-week period. Our data suggests that after single inoculation of 50ug DNA, plasma concentration of ~10ug/ml was achieved in vivo with peak serum expression around day 21 and expressed for extended duration.

Conclusions:

Our data highlights the design and characterization of novel DNA launched immunotherapeutic against HIV-1, which possess significant characteristics of a promising immunotherapy having broad neutralization capacities of a Tier 2/3 global virus panel, specific engagement of effector cells and killing of the infected target cells and longer serum half-life in comparison to conventional bispecific T cell engaging molecules. Delivery of LHL-BnKs as combination therapy